Last reviewed · How we verify
An Open Label,Switch Study of the Safety and Efficacy of Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy in Patient With Glaucoma or Ocular Hypertension.
This study is to evaluate the efficacy and safety of Combigan ophthalmic solution in combination with Latanoprost when the therapy is swiched from Latanoprost monotherapy in patient with Glaucoma or ocular hypertension. Hypothesis: 1. Combigan Ophthalmic Solution provides addition IOP loweringwhen combined with Latanoprost. 2. The treatment with Combigan Ophthalmic Solution has an acceptable safety profile, as measured by ocular and systemic safety parameters.
Details
| Lead sponsor | Genovate Biotechnology Co., Ltd., |
|---|---|
| Phase | Phase 4 |
| Status | UNKNOWN |
| Enrolment | 43 |
| Start date | 2006-05 |
| Completion | 2006-11 |
Conditions
- Glaucoma
Interventions
- Combigan Ophthalmic Solutiom
Primary outcomes
- The change of IntraOcular Pressure From baseline to week 12
Countries
Taiwan